Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Nordion Reports Strategic Realignment of the Company

By BiotechDaily International staff writers
Posted on 24 Sep 2012
Nordion, Inc. (Ottawa, Ontario, Canada), a global health science company, announced a strategic realignment of the business designed to focus on improving the execution of Nordion’s business strategy.

The plan includes transitioning Nordion to a business unit model with two distinct business units: targeted therapies and specialty isotopes, each of which will be supported by centralized corporate functions. The specialty isotopes business will include two segments: sterilization technologies and medical isotopes.

The company also announced the appointment of Jeff Brown, chief executive officer and founding member of Brown Equity Partners, LLC (Corona Del Mar, CA, USA), to its board of directors.

“The strategic realignment is designed to take into account the unique product life cycles and the needs of our customers in each of our businesses,” said Steve West, chief executive officer, Nordion. “The new organizational model is intended to allow for quicker decision making and provide the Nordion team with improved agility, clearer focus, and direct leadership accountability to better serve our customers and build shareholder value.”

The new Nordion leadership team intends to focus on appropriately allocating talent and resources to better support the unique characteristics of each business and their respective portfolios. Moreover, they plan to continue to evaluate opportunities that are expected to better serve our customers.

These announcements align with Nordion’s strategic priorities. The targeted therapies business unit is expected to continue to focus on building an interventional oncology business. The specialty isotopes business plans to concentrate on maintaining sterilization technologies’ cash generation, making selective growth investments and optimizing the medical isotope business.

Nordion plans to begin operating in the new business unit model on November 1, 2012, for the start of the company’s 2013 fiscal year. Nordion expects to continue to report financial results by its three business segments targeted therapies, sterilization technologies, and medical isotopes. Targeted Therapies will focus on TheraSphere while contract manufacturing is expected to be repositioned and reported under medical isotopes. The company’s segment reporting will incorporate the changes in the portfolios managed under each segment and comparative historic segment financial information is expected to be restated to align with these changes.

Nordion is a global health science company that provides products used for the prevention, diagnosis, and treatment of disease. The company is a leading provider of medical isotopes, targeted therapies, and sterilization technologies.

Related Links:

Nordion




Channels

Genomics/Proteomics

view channel
Image: The osteochondroretricular stem cell is a newly identified type of bone stem cell that appears to be vital to skeletal development and may provide the basis for novel treatments for osteoarthritis, osteoporosis, and bone fractures. In this illustration of the head of a femur, osteochondroretricular stem cells are visualized in red (Photo courtesy of Dr. Timothy Wang, Columbia University).

Gremlin 1 Expression Distinguishes Stem Cells Able to Regenerate Bones and Cartilage in Adult Mice

A newly identified type of stem cell in the bone marrow of adult mice was found to be capable of regenerating both bone and cartilage. Investigators at Columbia University (New York, NY, USA) reported... Read more

Drug Discovery

view channel

Curcumin Used to Treat Alzheimer’s Disease

Curcumin, a natural substance found in the spice turmeric, has been used by many Asian cultures for centuries. Now, new research suggests that a close chemical analog of curcumin has properties that may make it useful as a treatment for Alzheimer’s disease. “Curcumin has demonstrated ability to enter the brain, bind... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.